EDISON EQUITY RESEARCH: ANGLE: ADR UPDATE - THIRD CLINICAL APPLICATION EMERGES

Angle has announced results from a metastatic breast cancer research study carried out by its KOL partner University of Southern California (USC) Norris Comprehensive Cancer Center. Headline data potentially prove that circulating cancer cells (CTCs) captured using Parsortix have the same biology compared to invasive tissue biopsy and can be used to guide the treatment. While this will have to be replicated in larger-scale trials, it represents a potential third clinical application, in which Parsortix can establish a new standard of care.

Angle is a pure-play specialist diagnostics company. The proprietary Parsortix cell separation platform can be used for the detection and harvesting of very rare cells from a blood sample, including circulating tumor cells (CTCs). The resulting liquid biopsy enables the analysis of these cells for precision cancer care.

To view our full report, please click here 

Click here to view all of Edison Investment Research's published reports 

 

Angle Plc Surrey (QX) (USOTC:ANPCY)
Historical Stock Chart
From Sep 2024 to Oct 2024 Click Here for more Angle Plc Surrey (QX) Charts.
Angle Plc Surrey (QX) (USOTC:ANPCY)
Historical Stock Chart
From Oct 2023 to Oct 2024 Click Here for more Angle Plc Surrey (QX) Charts.